Anti-cytotoxic T lymphocyte antigen-4 antibodies in melanoma.

Although the study design had no power to detect differences in overall survival, a positive trend for both overall survival and progression free interval was noted for ipilimumab at the highest dose. 44 This was the first randomized clinical trial to evaluate the dose responsiveness of ipilimumab.

also in 11,005 other papers